{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:55:54Z","timestamp":1793422554254,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T00:00:00Z","timestamp":1566172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Diabetol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s00592-019-01402-w","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T02:02:38Z","timestamp":1566180158000},"page":"1239-1245","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["The multifaceted nature of diabetes mellitus induced by checkpoint inhibitors"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-5002","authenticated-orcid":false,"given":"Lucien","family":"Marchand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Disse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dalle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Reffet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Vouillarmet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fabien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Thivolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Cugnet-Anceau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,19]]},"reference":[{"issue":"2","key":"1402_CR1","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378(2):158\u2013168","journal-title":"N Engl J Med"},{"key":"1402_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.phrs.2014.07.004","volume":"98","author":"M Ben Nasr","year":"2015","unstructured":"Ben Nasr M, D\u2019Addio F, Usuelli V, Tezza S, Abdi R, Fiorina P (2015) The rise, fall, and resurgence of immunotherapy in type 1 diabetes. Pharmacol Res 98:31\u201338","journal-title":"Pharmacol Res"},{"issue":"9789","key":"1402_CR3","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/S0140-6736(11)60886-6","volume":"378","author":"T Orban","year":"2011","unstructured":"Orban T, Bundy B, Becker DJ et al (2011) Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. Lancet 378(9789):412\u2013419","journal-title":"Lancet"},{"issue":"5","key":"1402_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","volume":"3","author":"EA Tivol","year":"1995","unstructured":"Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH (1995) Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5):541\u2013547","journal-title":"Immunity"},{"issue":"1","key":"1402_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1084\/jem.20022125","volume":"198","author":"MJ Ansari","year":"2003","unstructured":"Ansari MJ, Salama AD, Chitnis T et al (2003) The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med 198(1):63\u201369","journal-title":"J Exp Med"},{"issue":"33","key":"1402_CR6","doi-asserted-by":"publisher","first-page":"11823","DOI":"10.1073\/pnas.0505497102","volume":"102","author":"J Wang","year":"2005","unstructured":"Wang J, Yoshida T, Nakaki F, Hiai H, Okazaki T, Honjo T (2005) Establishment of NOD-Pdcd1-\/-mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA 102(33):11823\u201311828","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1402_CR7","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clim.2007.05.013","volume":"125","author":"I Guleria","year":"2007","unstructured":"Guleria I, Gubbels Bupp M, Dada S et al (2007) Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol 125(1):16\u201325","journal-title":"Clin Immunol"},{"issue":"416","key":"1402_CR8","doi-asserted-by":"publisher","first-page":"eaam7543","DOI":"10.1126\/scitranslmed.aam7543","volume":"9","author":"M Ben Nasr","year":"2017","unstructured":"Ben Nasr M, Tezza S, D\u2019Addio F et al (2017) PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor cells reverses autoimmune diabetes. Sci Transl Med 9(416):eaam7543","journal-title":"Sci Transl Med"},{"issue":"3","key":"1402_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/cei.12603","volume":"180","author":"R Fujisawa","year":"2015","unstructured":"Fujisawa R, Haseda F, Tsutsumi C et al (2015) Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes. Clin Exp Immunol 180(3):452\u2013457","journal-title":"Clin Exp Immunol"},{"issue":"8","key":"1402_CR10","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.2337\/dbi18-0002","volume":"67","author":"AM Stamatouli","year":"2018","unstructured":"Stamatouli AM, Quandt Z, Perdigoto AL et al (2018) Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes 67(8):1471\u20131480","journal-title":"Diabetes"},{"issue":"12","key":"1402_CR11","doi-asserted-by":"publisher","first-page":"e150","DOI":"10.2337\/dc18-1465","volume":"41","author":"JJ Wright","year":"2018","unstructured":"Wright JJ, Salem JE, Johnson DB et al (2018) Increased reporting of immune checkpoint inhibitor-associated diabetes. Diabetes Care 41(12):e150\u2013e151","journal-title":"Diabetes Care"},{"issue":"5","key":"1402_CR12","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJM200002033420501","volume":"342","author":"A Imagawa","year":"2000","unstructured":"Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y (2000) A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM study group. N Engl J Med 342(5):301\u2013307","journal-title":"N Engl J Med"},{"issue":"4","key":"1402_CR13","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.2337\/dc14-2349","volume":"38","author":"J Hughes","year":"2015","unstructured":"Hughes J, Vudattu N, Sznol M et al (2015) Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 38(4):e55\u2013e57","journal-title":"Diabetes Care"},{"issue":"6","key":"1402_CR14","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/jdi.12531","volume":"7","author":"M Okamoto","year":"2016","unstructured":"Okamoto M, Okamoto M, Gotoh K et al (2016) Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig 7(6):915\u2013918","journal-title":"J Diabetes Investig"},{"issue":"11","key":"1402_CR15","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1007\/s00262-017-2033-8","volume":"66","author":"ML Gauci","year":"2017","unstructured":"Gauci ML, Laly P, Vidal-Trecan T et al (2017) Autoimmune diabetes induced by PD-1 inhibitor-retrospective analysis and pathogenesis: a case report and literature review. Cancer Immunol Immunother 66(11):1399\u20131410","journal-title":"Cancer Immunol Immunother"},{"key":"1402_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40425-016-0196-z","volume":"4","author":"JR Lowe","year":"2016","unstructured":"Lowe JR, Perry DJ, Salama AK, Mathews CE, Moss LG, Hanks BA (2016) Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immunother Cancer 4:89","journal-title":"J Immunother Cancer"},{"issue":"4","key":"1402_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00592-018-1234-8","volume":"56","author":"L Marchand","year":"2018","unstructured":"Marchand L, Thivolet A, Dalle S et al (2018) Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype. Acta Diabetol 56(4):441\u2013448","journal-title":"Acta Diabetol"},{"issue":"8","key":"1402_CR18","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.2337\/db11-1538","volume":"61","author":"CJ Greenbaum","year":"2012","unstructured":"Greenbaum CJ, Beam CA, Boulware D et al (2012) Fall in c-peptide during first 2\u00a0years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes trialnet data. Diabetes 61(8):2066\u20132073","journal-title":"Diabetes"},{"issue":"3","key":"1402_CR19","doi-asserted-by":"publisher","first-page":"638","DOI":"10.2337\/dc17-2243","volume":"41","author":"L Marchand","year":"2018","unstructured":"Marchand L, Thivolet A, Saintigny P, Fabien N, Vouillarmet J, Thivolet C (2018) Anti-programmed death 1 (PD-1) antibodies and the pancreas: a diabetic storm ahead? Diabetes Care 41(3):638\u2013639","journal-title":"Diabetes Care"},{"issue":"1","key":"1402_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-016-1913-7","volume":"66","author":"YK Chae","year":"2017","unstructured":"Chae YK, Chiec L, Mohindra N, Gentzler R, Patel J, Giles F (2017) A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother 66(1):25\u201332","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"1402_CR21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2217\/imt-2017-0042","volume":"9","author":"MA Smith-Cohn","year":"2017","unstructured":"Smith-Cohn MA, Gill D, Voorhies BN, Agarwal N, Garrido-Laguna I (2017) Case report: pembrolizumab-induced type 1 diabetes in a patient with metastatic cholangiocarcinoma. Immunotherapy 9(10):797\u2013804","journal-title":"Immunotherapy"},{"key":"1402_CR22","first-page":"2016","volume":"23","author":"J Aleksova","year":"2016","unstructured":"Aleksova J, Lau PK, Soldatos G, McArthur G (2016) Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. BMJ Case Rep 23:2016","journal-title":"BMJ Case Rep"},{"issue":"4","key":"1402_CR23","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00592-018-1246-4","volume":"56","author":"F Tassone","year":"2018","unstructured":"Tassone F, Colantonio I, Gamarra E et al (2018) Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring. Acta Diabetol 56(4):489\u2013490","journal-title":"Acta Diabetol"},{"issue":"3","key":"1402_CR24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s00592-018-1262-4","volume":"56","author":"L Marchand","year":"2018","unstructured":"Marchand L, Reffet S, Dalle S et al (2018) Fulminant diabetes induced by PD-1 and PD-L1 inhibitors: what about glucose variability? Acta Diabetol 56(3):377\u2013378","journal-title":"Acta Diabetol"},{"issue":"11","key":"1402_CR25","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.1016\/j.jtho.2017.07.021","volume":"12","author":"L Marchand","year":"2017","unstructured":"Marchand L, Paulus V, Fabien N et al (2017) Nivolumab-induced acute diabetes mellitus and hypophysitis in a patient with advanced pulmonary pleomorphic carcinoma with a prolonged tumor response. J Thorac Oncol 12(11):e182\u2013e184","journal-title":"J Thorac Oncol"},{"issue":"1","key":"1402_CR26","doi-asserted-by":"publisher","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","volume":"7","author":"A Kotwal","year":"2019","unstructured":"Kotwal A, Haddox C, Block M, Kudva YC (2019) Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes. BMJ Open Diabetes Res Care 7(1):e000591","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"5","key":"1402_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1097\/CJI.0000000000000218","volume":"41","author":"Q Magis","year":"2018","unstructured":"Magis Q, Gaudy-Marqueste C, Basire A et al (2018) Diabetes and blood glucose disorders under anti-PD1. J Immunother 41(5):232\u2013240","journal-title":"J Immunother"},{"issue":"3","key":"1402_CR28","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/CMR.0000000000000585","volume":"29","author":"ML Gauci","year":"2019","unstructured":"Gauci ML, Boudou P, Squara PA et al (2019) Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients. Melanoma Res 29(3):328\u2013332","journal-title":"Melanoma Res"},{"key":"1402_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.ejca.2018.09.014","volume":"104","author":"L Dehghani","year":"2018","unstructured":"Dehghani L, Mikail N, Kramkimel N et al (2018) Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment. Eur J Cancer 104:243\u2013246","journal-title":"Eur J Cancer"},{"issue":"8","key":"1402_CR30","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.1210\/jc.2018-02221","volume":"104","author":"CK Falcao","year":"2019","unstructured":"Falcao CK, Cabral MCS, Mota JM et al (2019) Acquired lipodystrophy associated with nivolumab in a patient with advanced renal cell carcinoma. J Clin Endocrinol Metab 104(8):3245\u20133248","journal-title":"J Clin Endocrinol Metab"},{"key":"1402_CR31","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2535","author":"A Jehl","year":"2019","unstructured":"Jehl A, Cugnet\u2010Anceau C, Vigouroux C et al (2019) Acquired generalized lipodystrophy: a new cause of Anti-PD-1 immune-related diabetes. Diabetes Care. https:\/\/doi.org\/10.2337\/dc18-2535","journal-title":"Diabetes Care"}],"container-title":["Acta Diabetologica"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-019-01402-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00592-019-01402-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00592-019-01402-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,25]],"date-time":"2022-09-25T21:31:07Z","timestamp":1664141467000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00592-019-01402-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,19]]},"references-count":31,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1402"],"URL":"https:\/\/doi.org\/10.1007\/s00592-019-01402-w","relation":{},"ISSN":["0940-5429","1432-5233"],"issn-type":[{"value":"0940-5429","type":"print"},{"value":"1432-5233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,19]]},"assertion":[{"value":"19 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no duality of interest associated with this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from all patients for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}